Nifty
Sensex
:
:
11987.65
40648.47
-11.45 (-0.10%)
-3.17 (-0.01%)

Pharmaceuticals & Drugs

Rating :
51/99  (View)

BSE: 532321 | NSE: CADILAHC

253.90
4.45 (1.78%)
21-Nov-2019 | 12:04PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  249.00
  •  254.80
  •  247.70
  •  249.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1181993
  •  3001.08
  •  369.00
  •  206.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 25,496.31
  • 18.45
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 32,746.41
  • 1.41%
  • 2.48

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.88%
  • 1.17%
  • 5.88%
  • FII
  • DII
  • Others
  • 4.39%
  • 8.20%
  • 5.48%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.57
  • 8.76
  • 11.98

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.89
  • 11.09
  • 9.31

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.54
  • 9.43
  • 7.42

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.04
  • 25.69
  • 23.49

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.82
  • 5.90
  • 4.85

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.09
  • 17.54
  • 16.95

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Net Sales
3,366.60
2,961.20
13.69%
3,496.30
2,893.70
20.82%
3,732.80
3,237.80
15.29%
3,577.90
3,259.90
9.75%
Expenses
2,741.00
2,273.40
20.57%
2,864.30
2,248.70
27.38%
2,932.40
2,382.70
23.07%
2,738.00
2,401.30
14.02%
EBITDA
625.60
687.80
-9.04%
632.00
645.00
-2.02%
800.40
855.10
-6.40%
839.90
858.60
-2.18%
EBIDTM
18.58%
23.23%
18.08%
22.29%
21.44%
26.41%
23.47%
26.34%
Other Income
26.90
30.40
-11.51%
22.60
101.30
-77.69%
38.40
44.00
-12.73%
31.00
25.70
20.62%
Interest
89.70
35.70
151.26%
89.10
35.00
154.57%
77.30
15.40
401.95%
45.50
13.40
239.55%
Depreciation
172.30
147.50
16.81%
171.60
141.80
21.02%
155.60
144.00
8.06%
153.70
146.90
4.63%
PBT
122.40
535.00
-77.12%
393.90
569.50
-30.83%
605.90
739.70
-18.09%
671.70
724.00
-7.22%
Tax
39.50
124.70
-68.32%
79.10
120.30
-34.25%
126.70
144.20
-12.14%
158.60
178.60
-11.20%
PAT
82.90
410.30
-79.80%
314.80
449.20
-29.92%
479.20
595.50
-19.53%
513.10
545.40
-5.92%
PATM
2.46%
13.86%
9.00%
15.52%
12.84%
18.39%
14.34%
16.73%
EPS
1.05
4.08
-74.26%
2.96
4.50
-34.22%
4.49
5.77
-22.18%
4.99
5.31
-6.03%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
14,173.60
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
7,224.00
6,357.70
5,263.30
4,630.60
3,686.80
Net Sales Growth
14.74%
10.13%
27.49%
-0.53%
8.96%
19.76%
13.63%
20.79%
13.66%
25.60%
 
Cost Of Goods Sold
5,153.90
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
2,036.80
1,464.10
1,286.20
1,011.20
Gross Profit
9,019.70
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
4,811.40
4,320.90
3,799.20
3,344.40
2,675.60
GP Margin
63.64%
68.54%
69.41%
67.31%
71.64%
67.47%
66.60%
67.96%
72.18%
72.22%
72.57%
Total Expenditure
11,275.70
10,197.60
9,125.90
7,475.00
7,097.30
6,897.40
6,031.20
5,234.00
4,181.50
3,614.10
2,878.20
Power & Fuel Cost
-
247.20
226.30
174.50
168.80
145.40
129.70
124.40
93.40
78.90
66.00
% Of Sales
-
1.88%
1.89%
1.86%
1.79%
1.68%
1.80%
1.96%
1.77%
1.70%
1.79%
Employee Cost
-
2,099.40
1,825.20
1,485.20
1,261.60
1,096.50
974.00
818.40
679.90
584.00
401.10
% Of Sales
-
15.95%
15.27%
15.84%
13.38%
12.67%
13.48%
12.87%
12.92%
12.61%
10.88%
Manufacturing Exp.
-
1,334.70
1,211.40
955.30
1,019.60
1,136.90
936.50
897.30
718.90
553.40
429.10
% Of Sales
-
10.14%
10.13%
10.19%
10.82%
13.14%
12.96%
14.11%
13.66%
11.95%
11.64%
General & Admin Exp.
-
589.10
504.60
466.00
432.70
326.80
365.70
342.20
271.90
234.90
218.50
% Of Sales
-
4.47%
4.22%
4.97%
4.59%
3.78%
5.06%
5.38%
5.17%
5.07%
5.93%
Selling & Distn. Exp.
-
1,035.40
1,014.50
826.40
979.60
960.30
902.40
857.50
767.40
710.70
585.30
% Of Sales
-
7.86%
8.49%
8.81%
10.39%
11.10%
12.49%
13.49%
14.58%
15.35%
15.88%
Miscellaneous Exp.
-
750.50
687.00
502.60
561.80
417.40
310.30
157.40
185.90
166.00
585.30
% Of Sales
-
5.70%
5.75%
5.36%
5.96%
4.82%
4.30%
2.48%
3.53%
3.58%
4.53%
EBITDA
2,897.90
2,968.00
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
1,123.70
1,081.80
1,016.50
808.60
EBITDA Margin
20.45%
22.54%
23.66%
20.28%
24.71%
20.27%
16.51%
17.67%
20.55%
21.95%
21.93%
Other Income
118.90
206.20
113.30
147.10
116.60
57.20
58.00
38.40
53.00
22.80
15.90
Interest
301.60
193.50
91.10
63.10
52.80
67.90
90.20
168.70
182.70
69.90
82.10
Depreciation
653.20
598.60
538.80
373.30
292.10
287.30
201.20
184.70
157.90
126.90
133.90
PBT
1,793.90
2,382.10
2,312.00
1,612.20
2,101.20
1,455.90
959.40
808.70
794.20
842.50
608.50
Tax
403.90
530.30
564.40
128.90
177.40
259.40
106.00
118.80
113.00
106.40
74.10
Tax Rate
22.52%
22.26%
24.41%
8.00%
8.45%
17.95%
11.25%
14.69%
14.23%
12.63%
12.27%
PAT
1,390.00
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
803.60
653.50
652.60
711.00
506.00
PAT before Minority Interest
1,349.00
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
836.20
689.90
681.20
736.10
529.80
Minority Interest
-41.00
-49.90
-34.60
-29.10
-30.40
-37.60
-32.60
-36.40
-28.60
-25.10
-23.80
PAT Margin
9.81%
13.69%
14.33%
15.51%
20.06%
13.28%
11.12%
10.28%
12.40%
15.35%
13.72%
PAT Growth
-30.51%
5.19%
17.82%
-23.11%
64.64%
42.92%
22.97%
0.14%
-8.21%
40.51%
 
Unadjusted EPS
13.49
18.06
17.35
14.53
19.19
11.24
39.25
31.92
31.87
34.73
24.67

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
2,944.50
2,585.90
2,171.50
1,628.50
Share Capital
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
68.20
Total Reserves
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
2,842.10
2,483.50
2,069.10
1,560.30
Non-Current Liabilities
3,491.10
2,122.20
1,903.30
736.10
1,341.50
1,589.20
1,640.00
1,555.10
956.30
1,204.60
Secured Loans
1,578.00
200.60
319.60
393.80
664.00
851.40
917.20
901.90
670.90
978.20
Unsecured Loans
2,371.70
2,354.50
2,148.80
502.60
486.40
510.80
508.80
420.40
92.00
112.30
Long Term Provisions
184.10
155.90
151.20
120.70
90.40
76.10
66.50
75.60
61.90
0.00
Current Liabilities
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
2,670.40
2,191.60
1,415.90
871.10
Trade Payables
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
910.80
656.80
545.50
570.60
619.60
Other Current Liabilities
2,033.60
1,484.90
1,212.10
860.70
628.20
708.10
509.20
730.90
367.30
56.40
Short Term Borrowings
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
902.40
1,257.10
687.10
259.80
0.00
Short Term Provisions
189.40
152.20
68.90
81.30
382.50
292.70
247.30
228.10
218.20
195.10
Total Liabilities
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60
3,743.40
Net Block
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
3,025.60
2,857.10
1,832.60
1,684.40
Gross Block
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
4,664.00
4,376.20
3,990.90
2,801.70
2,557.80
Accumulated Depreciation
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
1,540.20
1,350.60
1,096.00
929.90
835.00
Non Current Assets
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
4,182.50
3,610.00
2,485.30
1,953.30
Capital Work in Progress
837.20
1,527.20
1,543.30
950.80
797.90
891.50
735.60
483.90
431.00
211.10
Non Current Investment
443.60
470.90
385.70
217.10
33.20
22.20
21.20
21.20
20.70
20.70
Long Term Loans & Adv.
410.40
300.00
384.70
661.20
637.10
511.10
400.10
247.80
201.00
0.00
Other Non Current Assets
159.80
130.30
234.10
174.70
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
3,191.70
2,813.00
2,125.30
1,779.90
Current Investments
229.90
274.80
49.10
199.10
121.20
64.40
93.30
3.00
0.00
0.00
Inventories
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
1,213.60
1,090.50
811.90
750.40
Sundry Debtors
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
955.10
920.90
765.20
466.80
Cash & Bank
649.30
1,314.90
1,543.50
638.70
669.90
548.80
583.80
466.60
295.20
250.70
Other Current Assets
980.10
520.70
80.00
124.10
311.50
323.50
345.90
332.00
253.00
312.00
Short Term Loans & Adv.
584.50
527.70
268.50
234.80
240.80
254.90
279.00
274.60
206.20
308.00
Net Current Assets
1,155.60
2,146.70
716.50
819.40
941.60
623.90
521.30
621.40
709.40
908.80
Total Assets
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60
3,743.40

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
2,882.30
919.30
1,311.70
1,893.50
993.60
902.80
603.40
511.10
682.60
695.40
PBT
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
942.20
808.70
794.20
842.50
603.90
Adjustment
664.30
624.30
333.70
249.80
344.50
269.00
315.90
320.90
208.40
228.10
Changes in Working Capital
637.80
-1,383.90
-411.20
271.70
-377.00
-20.10
-201.60
-421.70
-175.30
-123.60
Cash after chg. in Working capital
3,684.20
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
923.00
693.40
875.60
708.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-675.40
-602.30
-237.60
-646.00
-386.90
-172.80
-272.00
-143.50
-152.50
-77.10
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
-126.50
-30.80
14.90
-80.70
-32.50
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-5,738.70
-973.70
-2,871.90
-863.50
-464.70
-438.00
-682.30
-1,199.50
-466.00
-371.60
Net Fixed Assets
-569.90
-600.20
-557.40
-531.50
-271.50
-239.50
-646.90
-361.70
-266.60
-223.80
Net Investments
-1,106.80
305.60
-1,606.20
-108.40
-651.40
-277.80
-67.70
-513.40
-99.90
-3.50
Others
-4,062.00
-679.10
-708.30
-223.60
458.20
79.30
32.30
-324.40
-99.50
-144.30
Cash from Financing Activity
1,884.60
51.50
2,315.80
-934.80
-351.10
-528.70
285.80
859.80
-172.10
-324.80
Net Cash Inflow / Outflow
-971.80
-2.90
755.60
95.20
177.80
-63.90
206.90
171.40
44.50
-1.00
Opening Cash & Equivalents
1,589.70
1,592.60
837.00
737.90
612.60
676.50
469.60
295.20
250.70
251.70
Closing Cash & Equivalent
879.20
1,589.70
1,592.60
837.00
790.40
612.60
676.50
466.60
295.20
250.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
101.43
85.40
67.97
55.66
41.52
33.58
28.75
25.25
21.21
15.82
ROA
9.34%
11.11%
12.18%
20.14%
13.93%
10.89%
10.00%
12.35%
17.62%
14.94%
ROE
19.36%
22.26%
23.43%
38.62%
30.85%
26.20%
24.95%
28.64%
38.85%
37.71%
ROCE
15.88%
18.26%
16.50%
28.60%
23.21%
17.20%
18.21%
24.01%
30.56%
26.55%
Fixed Asset Turnover
1.05
1.38
1.38
1.76
1.80
1.63
1.55
1.58
1.75
1.54
Receivable days
99.21
83.37
76.72
63.29
56.38
51.71
52.78
57.47
47.97
45.13
Inventory Days
70.33
63.69
59.88
54.52
60.13
63.89
64.82
64.85
60.83
66.19
Payable days
72.33
71.11
74.18
67.53
55.78
50.51
43.54
49.87
64.40
75.83
Cash Conversion Cycle
97.21
75.95
62.42
50.28
60.73
65.09
74.05
72.45
44.40
35.49
Total Debt/Equity
0.76
0.62
0.75
0.43
0.62
0.79
0.99
0.89
0.50
0.67
Interest Cover
13.31
26.38
26.55
40.75
22.29
11.45
5.79
5.35
13.05
8.36

News Update


  • Zydus Cadila gets USFDA’s nod for Isosorbide Dinitrate Tablets, Desonide Cream
    21st Nov 2019, 11:20 AM

    The group now has 278 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Cadila declares second Phase 3 trial of Desidustat
    18th Nov 2019, 12:06 PM

    Desidustat is a novel, oral, HIF-PH inhibitor being developed for treating anemia in CKD patients

    Read More
  • Zydus Cadila gets tentative approval from USFDA for Apremilast Tablets
    16th Nov 2019, 15:40 PM

    It will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad

    Read More
  • Cadila Healthcare acquires remaining stake in two subsidiaries
    14th Nov 2019, 14:46 PM

    In view of the same, both ZTL and ZNI will become wholly owned subsidiary companies of the company

    Read More
  • Zydus Cadila gets USFDA’s nod for Cisatracurium Besylate Injection
    5th Nov 2019, 11:46 AM

    This medication is used to relax the muscles

    Read More
  • Cadila Healthcare gets warning letter from USFDA for Moraiya formulation facility
    4th Nov 2019, 15:24 PM

    The company has taken multiple steps after the inspection to address the observations received from USFDA during the inspection

    Read More
  • Cadila Healthcare receives EIR for Baddi unit
    31st Oct 2019, 11:46 AM

    The USFDA had conducted an inspection at the facility from July 15, 2019 to July 19, 2019

    Read More
  • Cadila Healthcare’s arm receives approval for Haloperidol Decanoate Injection
    24th Oct 2019, 09:08 AM

    It will be manufactured at Liva Pharma's manufacturing facility at Vadodara

    Read More
  • Zydus to present EVIDENCES IV clinical trial results of Saroglitazar Magnesium in NAFLD, NASH
    23rd Oct 2019, 14:47 PM

    Earlier Zydus had reported that the EVIDENCES IV clinical trial had achieved the primary end-points in patients with NAFLD and NASH

    Read More
  • USFDA completes inspection at Cadila Healthcare’s API facility at Dabhasa
    14th Oct 2019, 09:11 AM

    At the end of the inspection, no observation is issued

    Read More
  • Zydus Cadila gets nod from USFDA for Colesevelam Hydrochloride Tablets
    9th Oct 2019, 14:05 PM

    Colesevelam Hydrochloride Tablets will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad

    Read More
  • Zydus Cadila gets positive results from EVIDENCES IV Phase 2 clinical trial of Saroglitazar Magnesium
    3rd Oct 2019, 10:26 AM

    The EVIDENCES IV NASH trial was a randomized, double-blind, placebo-controlled study that enrolled 106 patients

    Read More
  • Cadila Healthcare to sell interest in ZYPITAMAG
    1st Oct 2019, 09:15 AM

    The company will receive an upfront payment of $5 million and $2 million in deferred payments to be made over the next four years

    Read More
  • Zydus Cadila gets final approval from USFDA for Clobetasol Propionate Lotion
    26th Sep 2019, 12:01 PM

    It will be manufactured at the group's Topical manufacturing facility at Ahmedabad

    Read More
  • Cadila Healthcare receives EIR for Ankleshwar unit
    23rd Sep 2019, 12:07 PM

    The EIR report stated that the classification of the facility is ’No Action Indicated’

    Read More
  • Zydus receives marketing authorization for RabiMabs from Drug Controller General of India
    3rd Sep 2019, 09:41 AM

    Twinrab, is indicated in combination with rabies vaccine for rabies post-exposure prophylaxis

    Read More
  • Zydus Cadila gets USFDA’s nod for Ranolazine Extended-Release Tablets
    21st Aug 2019, 14:00 PM

    It will be manufactured at the group’s formulations manufacturing facility at Baddi

    Read More
  • Zydus Cadila initiates Phase 2 clinical trial of Saroglitazar Magnesium in NAFLD with PCOS
    21st Aug 2019, 11:49 AM

    The EVIDENCES VII trial is currently recruiting patients across several clinical sites in the United States of America and Mexico

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.